Long-term, single-arm, open-label, multicenter phase 2/4 study of glatiramer acetate by subcutaneous injection in Japanese patients with relapsing–remitting multiple sclerosis

Takashi Yamamura, Toshiyuki Fukazawa, Masami Tanaka, Takashi Ohashi, Shinichiro Tanaka, Michihiro Yoshida, Hideki Houzen

Research output: Contribution to journalArticle

Abstract

Objective: Glatiramer acetate (GA) has been shown to be a well-tolerated and effective treatment for patients with multiple sclerosis (MS) with relapse. The present open-label study aimed to evaluate the efficacy and safety of long-term treatment with GA. Methods: Japanese patients with relapsing–remitting MS received up to 52-weeks’ treatment with GA 20 mg/mL once daily in the phase 2 study. In phase 4, patients continued to receive treatment after marketing approval in Japan until commercial availability. Key end-points were safety and tolerability of GA. Other analyses included numbers and volumes of gadolinium-enhancing and T2-weighted (T2) lesions. Results: Of 17 patients initially treated, 13 completed 52 weeks’ therapy and 10 completed the phase 4 extension (efficacy assessment: 104 weeks; maximum treatment period/long-term safety assessment: up to 5 years). No new safety signals were observed; most adverse events were mild or moderate, with injection site reactions being the most common. The number of T1 gadolinium-enhancing lesions declined from 2.9 (baseline) to 1.3 (week 104), and the number of T2 lesions increased from 1.7 to 6.7. T1 and T2 lesion volume changes were not clinically meaningful (changes of −0.090 and 0.088 mL, respectively, by week 104). The mean annualized relapse rate was 2.01 (baseline) and 1.78 (week 104); the mean Expanded Disability Status Scale scores indicated reduced levels of disability. Conclusions: These findings suggest the favorable tolerability and safety profile of GA in Japanese patients, and provide supportive evidence for the efficacy of GA in reducing MS recurrence and improving disability in Japanese MS patients.

Original languageEnglish
Pages (from-to)49-56
Number of pages8
JournalClinical and Experimental Neuroimmunology
Volume10
Issue number1
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

Subcutaneous Injections
Multiple Sclerosis
Safety
Gadolinium
Recurrence
Therapeutics
Marketing
Glatiramer Acetate
Japan
Injections

Keywords

  • extension study
  • gadolinium-enhancing lesions
  • glatiramer acetate
  • Japanese patients
  • relapsing–remitting multiple sclerosis

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology
  • Immunology and Microbiology (miscellaneous)
  • Clinical Neurology

Cite this

Long-term, single-arm, open-label, multicenter phase 2/4 study of glatiramer acetate by subcutaneous injection in Japanese patients with relapsing–remitting multiple sclerosis. / Yamamura, Takashi; Fukazawa, Toshiyuki; Tanaka, Masami; Ohashi, Takashi; Tanaka, Shinichiro; Yoshida, Michihiro; Houzen, Hideki.

In: Clinical and Experimental Neuroimmunology, Vol. 10, No. 1, 01.02.2019, p. 49-56.

Research output: Contribution to journalArticle

@article{15900fcf95694cfeac273dc449cd21eb,
title = "Long-term, single-arm, open-label, multicenter phase 2/4 study of glatiramer acetate by subcutaneous injection in Japanese patients with relapsing–remitting multiple sclerosis",
abstract = "Objective: Glatiramer acetate (GA) has been shown to be a well-tolerated and effective treatment for patients with multiple sclerosis (MS) with relapse. The present open-label study aimed to evaluate the efficacy and safety of long-term treatment with GA. Methods: Japanese patients with relapsing–remitting MS received up to 52-weeks’ treatment with GA 20 mg/mL once daily in the phase 2 study. In phase 4, patients continued to receive treatment after marketing approval in Japan until commercial availability. Key end-points were safety and tolerability of GA. Other analyses included numbers and volumes of gadolinium-enhancing and T2-weighted (T2) lesions. Results: Of 17 patients initially treated, 13 completed 52 weeks’ therapy and 10 completed the phase 4 extension (efficacy assessment: 104 weeks; maximum treatment period/long-term safety assessment: up to 5 years). No new safety signals were observed; most adverse events were mild or moderate, with injection site reactions being the most common. The number of T1 gadolinium-enhancing lesions declined from 2.9 (baseline) to 1.3 (week 104), and the number of T2 lesions increased from 1.7 to 6.7. T1 and T2 lesion volume changes were not clinically meaningful (changes of −0.090 and 0.088 mL, respectively, by week 104). The mean annualized relapse rate was 2.01 (baseline) and 1.78 (week 104); the mean Expanded Disability Status Scale scores indicated reduced levels of disability. Conclusions: These findings suggest the favorable tolerability and safety profile of GA in Japanese patients, and provide supportive evidence for the efficacy of GA in reducing MS recurrence and improving disability in Japanese MS patients.",
keywords = "extension study, gadolinium-enhancing lesions, glatiramer acetate, Japanese patients, relapsing–remitting multiple sclerosis",
author = "Takashi Yamamura and Toshiyuki Fukazawa and Masami Tanaka and Takashi Ohashi and Shinichiro Tanaka and Michihiro Yoshida and Hideki Houzen",
year = "2019",
month = "2",
day = "1",
doi = "10.1111/cen3.12485",
language = "English",
volume = "10",
pages = "49--56",
journal = "Clinical and Experimental Neuroimmunology",
issn = "1759-1961",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Long-term, single-arm, open-label, multicenter phase 2/4 study of glatiramer acetate by subcutaneous injection in Japanese patients with relapsing–remitting multiple sclerosis

AU - Yamamura, Takashi

AU - Fukazawa, Toshiyuki

AU - Tanaka, Masami

AU - Ohashi, Takashi

AU - Tanaka, Shinichiro

AU - Yoshida, Michihiro

AU - Houzen, Hideki

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Objective: Glatiramer acetate (GA) has been shown to be a well-tolerated and effective treatment for patients with multiple sclerosis (MS) with relapse. The present open-label study aimed to evaluate the efficacy and safety of long-term treatment with GA. Methods: Japanese patients with relapsing–remitting MS received up to 52-weeks’ treatment with GA 20 mg/mL once daily in the phase 2 study. In phase 4, patients continued to receive treatment after marketing approval in Japan until commercial availability. Key end-points were safety and tolerability of GA. Other analyses included numbers and volumes of gadolinium-enhancing and T2-weighted (T2) lesions. Results: Of 17 patients initially treated, 13 completed 52 weeks’ therapy and 10 completed the phase 4 extension (efficacy assessment: 104 weeks; maximum treatment period/long-term safety assessment: up to 5 years). No new safety signals were observed; most adverse events were mild or moderate, with injection site reactions being the most common. The number of T1 gadolinium-enhancing lesions declined from 2.9 (baseline) to 1.3 (week 104), and the number of T2 lesions increased from 1.7 to 6.7. T1 and T2 lesion volume changes were not clinically meaningful (changes of −0.090 and 0.088 mL, respectively, by week 104). The mean annualized relapse rate was 2.01 (baseline) and 1.78 (week 104); the mean Expanded Disability Status Scale scores indicated reduced levels of disability. Conclusions: These findings suggest the favorable tolerability and safety profile of GA in Japanese patients, and provide supportive evidence for the efficacy of GA in reducing MS recurrence and improving disability in Japanese MS patients.

AB - Objective: Glatiramer acetate (GA) has been shown to be a well-tolerated and effective treatment for patients with multiple sclerosis (MS) with relapse. The present open-label study aimed to evaluate the efficacy and safety of long-term treatment with GA. Methods: Japanese patients with relapsing–remitting MS received up to 52-weeks’ treatment with GA 20 mg/mL once daily in the phase 2 study. In phase 4, patients continued to receive treatment after marketing approval in Japan until commercial availability. Key end-points were safety and tolerability of GA. Other analyses included numbers and volumes of gadolinium-enhancing and T2-weighted (T2) lesions. Results: Of 17 patients initially treated, 13 completed 52 weeks’ therapy and 10 completed the phase 4 extension (efficacy assessment: 104 weeks; maximum treatment period/long-term safety assessment: up to 5 years). No new safety signals were observed; most adverse events were mild or moderate, with injection site reactions being the most common. The number of T1 gadolinium-enhancing lesions declined from 2.9 (baseline) to 1.3 (week 104), and the number of T2 lesions increased from 1.7 to 6.7. T1 and T2 lesion volume changes were not clinically meaningful (changes of −0.090 and 0.088 mL, respectively, by week 104). The mean annualized relapse rate was 2.01 (baseline) and 1.78 (week 104); the mean Expanded Disability Status Scale scores indicated reduced levels of disability. Conclusions: These findings suggest the favorable tolerability and safety profile of GA in Japanese patients, and provide supportive evidence for the efficacy of GA in reducing MS recurrence and improving disability in Japanese MS patients.

KW - extension study

KW - gadolinium-enhancing lesions

KW - glatiramer acetate

KW - Japanese patients

KW - relapsing–remitting multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85056701257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056701257&partnerID=8YFLogxK

U2 - 10.1111/cen3.12485

DO - 10.1111/cen3.12485

M3 - Article

VL - 10

SP - 49

EP - 56

JO - Clinical and Experimental Neuroimmunology

JF - Clinical and Experimental Neuroimmunology

SN - 1759-1961

IS - 1

ER -